Could Higher Buprenorphine Doses Keep More People in Opioid Treatment?
Could Higher Buprenorphine Doses Keep More People in Opioid Treatment?
In opioid addiction treatment, one fact matters more than almost any other: staying in care saves lives.
That is what makes the growing debate over higher-dose buprenorphine so important. This is not really a story about whether the medicine works — that question is largely settled. Buprenorphine is already one of the most effective medications available for opioid use disorder. The more urgent question is whether some patients, particularly in a drug market reshaped by fentanyl, are receiving doses too low to keep them stable.
It is a highly practical issue with very real consequences. If the dose is not enough to suppress withdrawal and reduce cravings, patients are more likely to continue using illicit opioids, more likely to disengage from treatment and more likely to end up back in crisis. And in opioid use disorder, crises are rarely minor.
Why dose has become a bigger issue now
The arrival of fentanyl has changed the treatment landscape. Because it is far more potent than many other opioids, it can leave patients with higher tolerance, more difficult withdrawal and greater instability. That matters because medication strategies developed in an earlier phase of the opioid epidemic may not work as well in a fentanyl-dominated environment.
Clinicians have increasingly reported that some patients appear under-treated on standard buprenorphine doses. They may still feel unwell, still experience powerful cravings, or still continue using opioids on top of treatment. When that happens, the problem may not be that buprenorphine has failed. It may be that the dose has not caught up with the clinical reality.
A recent review focused specifically on high-dose buprenorphine in the fentanyl era adds weight to that concern. It suggests that higher-dose approaches may be associated with better retention in treatment and lower healthcare use than standard approaches. That does not prove that more is always better. But it does support the idea that dose optimisation may now be more important than many systems have allowed for.
Why retention is such a critical outcome
In other conditions, staying on treatment matters because it improves symptom control. In opioid use disorder, it can do far more than that.
Remaining in treatment is consistently linked to better outcomes. People who stay engaged with medication treatment are less likely to relapse, less likely to require acute care and less likely to die from overdose. In that sense, retention is not just an operational measure for clinics. It is one of the clearest indicators that treatment is protecting someone from a dangerous and unstable drug supply.
This is one reason buprenorphine has become such a central medication in addiction care. It works by easing withdrawal symptoms and reducing cravings, helping to create enough stability for a person to remain in treatment and reduce their exposure to harm. But it only does that reliably if the dose is sufficient.
That sounds obvious, but it has not always been reflected in policy or practice.
The overlooked problem of underdosing
One of the more important findings in the wider literature is how much buprenorphine dosing varies between countries, services and clinicians. Global opioid agonist treatment data suggest that underdosing remains a persistent problem. That matters because a dose that is technically prescribed may still be clinically inadequate.
This has implications for how treatment failure is understood. It is easy to assume that if a patient drops out or continues using opioids, the problem lies with motivation, engagement or behavioural instability. Sometimes that is part of the picture. But not always.
Sometimes the patient has been started on too little medication to meaningfully control symptoms. In those cases, apparent non-adherence may partly reflect under-treatment.
That should shift the conversation. It suggests that some treatment systems may be too quick to view continued instability as a patient problem, and not quick enough to ask whether the pharmacological support was strong enough in the first place.
What the evidence supports — and where it stops short
The evidence supplied here makes a persuasive case for a few core points. Buprenorphine is effective treatment for opioid use disorder. Pharmacotherapy helps people stay in care and reduces harm. And there is a plausible, increasingly supported argument that higher buprenorphine doses may help some patients remain in treatment longer, especially in fentanyl-exposed settings.
But there are important limits.
The strongest evidence focused specifically on higher doses comes largely from reviews of observational studies, not large randomised clinical trials. That means the findings are clinically relevant, but not definitive.
Observational research can be extremely useful, especially in fast-moving public health crises where waiting years for perfect evidence is not always realistic. Still, it has weaknesses. Patients on higher doses may differ in important ways from patients on lower doses. Methodological issues such as confounding and immortal time bias can also distort results, making benefits appear stronger than they really are.
There is another reason for caution. Much of this conversation is shaped by the fentanyl context. That does not invalidate the findings, but it does mean they may not apply equally across every opioid-using population or every treatment setting.
And importantly, the available research does not identify one universally optimal dose. It supports individualised treatment, not a blanket instruction to increase everyone’s prescription.
What this means in practice
For clinicians, the practical lesson is straightforward: dosing should be guided by response, not habit.
Is the patient’s withdrawal controlled? Are cravings manageable? Are they continuing to use illicit opioids? Are they stable enough to stay engaged with treatment? If the answer to those questions is no, then simply noting that the patient is “on buprenorphine” may not mean very much.
The more useful question may be whether they are on enough buprenorphine.
This matters in the UK as well, even though the shape of the opioid crisis differs from North America. Britain’s opioid-related harms have their own patterns, and fentanyl does not define every part of the domestic picture. But the broader lesson still applies: treatment has to match the potency, unpredictability and clinical realities of the drug supply people are actually facing.
There is also a patient-centred point here that should not be overlooked. Needing a higher dose is not a sign of weakness, bad behaviour or a more shameful form of addiction. It is a clinical issue shaped by tolerance, exposure and biology. In a field still saturated with stigma, that distinction matters.
A systems issue, not just a prescribing issue
This debate is about more than what happens in one consultation. It also raises questions about how addiction services are structured.
If services rely on rigid dose ceilings, outdated guidance or an overly cautious culture around buprenorphine, they may inadvertently create conditions in which some patients are left under-treated. When that happens, access to treatment exists in theory but falls short in practice.
That is especially troubling because the consequences are not abstract. Inadequate dosing can contribute to treatment dropout, and treatment dropout can place someone back in direct contact with a high-risk illicit market.
Of course, no one should pretend that dose is the whole answer. Good opioid treatment also depends on continuity of care, harm reduction support, mental health input, stable relationships with services and a system that does not punish relapse as moral failure. But medication adequacy is one of the foundations of all of that. If withdrawal and cravings remain poorly controlled, everything else becomes harder.
The bigger change in thinking
What this emerging evidence really reflects is a broader shift in addiction medicine. The field is moving away from a simple question — has treatment been offered? — towards a more demanding one: has it been optimised for the patient in front of us?
In the fentanyl era, that shift is hard to avoid. Old dosing assumptions may not be robust enough for current realities. And if higher doses help some patients stay in treatment, then the issue is not whether those doses sound unusually high on paper. The issue is whether they help keep people alive and engaged in care.
The bottom line
Higher-dose buprenorphine should not be sold as a universal answer for every person with opioid use disorder. The evidence is still largely observational, and it does not point to one ideal dose for everyone.
But it does support something important: for some patients, particularly where fentanyl complicates treatment, higher doses may improve retention in care. And because retention is one of the most meaningful predictors of better outcomes in opioid addiction treatment, that possibility deserves serious attention.
This is not really a story about prescribing more. It is a story about treating people well enough to give them a realistic chance of staying in treatment at all.